Quest Diagnostics (DGX) Tops Q1 EPS by 15c; Raises FY17 EPS Outlook

Quest Diagnostics (NYSE: DGX) reported Q1 EPS of $1.33, $0.15 better than the analyst estimate of $1.18. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.87 billion.

"We delivered strong growth across the board in the first quarter with gains in revenues, EPS, operating income, margins and operating cash flow," said Steve Rusckowski, Chairman, President and CEO. "Growth in the quarter was driven by expanding relationships with hospital health systems. Our agreement with PeaceHealth in the Pacific Northwest announced in the first quarter will further bolster growth later in the year."

GUIDANCE:

Quest Diagnostics sees FY2017 EPS of $5.45-$5.60, versus the consensus of $5.46 and prior of $5.37-$5.52. Quest Diagnostics sees FY2017 revenue of $7.64-7.72 billion, versus the consensus of $7.67 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Worried the AI trade has gone too far? Evercore likes these 4 stocks
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target